Empagliflozin in Patients With Cirrhosis and Ascites
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
A proof-of-concept placebo-controlled trial to explore the acute and 14-day effects of
empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites. We
will additionally investigate its effect on neurohumoral activation, and renal hemodynamics.